



# Radiobiological modeling of radiation damage to the cardio-pulmonary system and the Hodgkin lymphoma paradigm

Laura Cella

*Consiglio Nazionale delle Ricerche*


**ISTITUTO DI BIOSTRUTTURE E BIOIMMAGINI**

In a modern radiotherapy setting, radiobiological models potentially play an essential role and normal tissue complication probability (NTCP) modeling may help to minimize side effects for individual patients.

# Adverse effects of radiotherapy to the chest

Radiation Induced  
Lung Toxicity (RILI)

Radiation Induced  
Heart Disease (RIHD)



Experimental studies in rats showed that irradiation of heart, lungs, or both independently induces specific cardiac dysfunction and associated pulmonary vascular damage, in a negative synergy

van Luijk P, IJROBP 2007, Ghobadi G, IJROBP 2012

However, clinical studies in radiotherapy patients are necessary in order to link these results to humans

# Studied patients population for RIHD & RILI

- Hodgkin's lymphoma

Heidenreich J Clin Oncol. 2007, Eriksson R&O 2000,  
Fox IJROBP 2012

- Breast cancer

Darby N Engl J Med. 2013 , Lind IJROBP 2006

- Lung cancer

Hope, IJROBP 2006, Dang Acta Oncol 2013

- Esophageal cancer

Konski R&O 2012, Wei IJROBP 2006 , Gayed I, Int J  
Cardiovasc Imaging 2009




Lung and heart have been historically considered separately in radiation induced side effects study

but....



# Organs' "partnership" should be considered





## For the proposition

LUNG  
CANCER  
PATIENTS

- Co-irradiation of heart enhances the risk and severity of RILI

*Hope, IJROBP 2006; Huang, Acta Oncol 2011*

- Cardiac comorbidity is an independent risk factor for RILI

*Nalbantov, R&O 2013*

- Radiation-induced fibrosis of the lung and its vessels may affect cardiac functions

*Adams, Crit Rev Oncol Hematol 2003*

## Against the proposition

- The incorporation of heart parameters did not significantly improve RILI risk prediction

*Tucker, Acta Oncol 2014*



# Clinical Radiobiology

Our basic idea is to perform a “clinical” radiation biology studies through the development of robust predictive Normal Tissue Complication Probability (NTCP) models

# Modeling: Data driven approach to NTCP

We have followed a multivariate modeling approach of radio-induced complication risk for heart-lung system without making a-priori hypotheses.

“A data-driven and exploratory approach to NTCP analyses allows for consideration of a wider range of dosimetric, spatial, and clinical-biological covariates within the same model-building exercise”

Deasy and El Naqa, Radiation Oncology Advances , Springer 2008

# Modeling steps

1. Model size estimated by bootstrapping
2. Model regression coefficients estimated using forward selection on multiple bootstraps sample (the most frequently selected model is the optimal one)
3. Model predictive power was quantified by use of Spearman's coefficient  $R_s$
4. AUC of ROC curve used to evaluate the discriminating ability of model fit

# Application of data-driven multivariate NTCP modeling exercise

- Input variables: lung + heart dosimetric parameters + clinical data
- Logistic regression model:

$$NTCP = \frac{1}{1+e^{-g(x)}} \quad g(x) = \beta_0 + \beta_1x_1 + \beta_2x_2 + \dots + \beta_nx_n$$

$x_1, x_2, \dots, x_n$  input variables,

$\beta_0, \beta_1, \dots, \beta_n$  the corresponding regression coefficients

$$LLH = \sum_{y_i=1} \ln NTCP + \sum_{y_i=0} \ln(1 - NTCP)$$

- Data analysis performed by CERR+DREES open source packages



ITALIAN PHYSICAL SOCIETY  
SOCIETÀ ITALIANA DI FISICA









# Traditional dose-volume based NTCP models

Lyman-Kutcher-Burman


Kutcher and Burman, IJROBP 1989

$$\text{NTCP} = \frac{1}{\sqrt{2\pi}} \int_{-\infty}^u e^{-t^2/2} dt$$

$$u = \frac{D - \text{TD50}(V)}{m \times \text{TD50}(V)}$$

$$\text{TD50}(V) = \text{TD50}(1)/V^n$$

$$V = \sum_i (D_i/D)^{1/n} \Delta V_i$$



(3 parameters: TD50(1), m, n)

# Why Hodgkin's lymphoma survivors

Compared with other thoracic malignancies, Hodgkin lymphoma (HL) patient population is generally characterized by:

- High cure rates (90%) and prolonged survival

Late chronic toxicities, including cardiovascular disease and lung injuries, are of major concern in patients treated for HL

- lower median age
- better performance status
- different smoking history
- different chemotherapy regimens
- lower radiation doses prescribed
- Intact lungs

These patient cohorts may play a pivotal role in modeling heart-lung complications after thoracic irradiation


# Our database

Consecutive HL patients treated with chemotherapy and subsequent supradiaphragmatic radiation therapy (2001-2013)

Radiation Oncology Department of  
Federico II University School of  
Medicine of Naples (117 pts)


+

S. Camillo-Forlanini Hospital in  
Rome (31 pts)





# A representative patient



## Patient characteristics

- Median total dose: 30.6 Gy (range 20.8-45.0 Gy)
- AP-PA fields with 6-20 MV photon beams
- Median Age: 28 years (13-71 years)
- Gender : 54% female, 46% male
- Chemotherapy: 38% ABVD, 59% VEBEP, 3% BEACOPP

# Inclusion criteria

- Availability of cardiac and lung evaluation before CHT, after CHT before RT, after RT
- Availability 3-dimensional treatment planning data (extraction of dosimetric parameters)
- follow-up at least:
  - ❖ 3 years endpoint RIHD
  - ❖ 2 years endpoint RILI



# Endpoint: RIHD ↔ Asymptomatic Valve Dysfunction

- A wide spectrum of adverse effects on the cardiovascular system (pericarditis, cardiomyopathy, coronary artery disease, valvular disease)
- The manifestations of RIHD ( most often become clinically apparent several years (~10) after irradiation
- In the spectrum of RIHD, asymptomatic valve defects may be regarded as an early predictor and/or precursor of clinically relevant cardiac dysfunction



Contents lists available at SciVerse ScienceDirect

Radiotherapy and Oncology

journal homepage: [www.thegreenjournal.com](http://www.thegreenjournal.com)



Morbidity of mediastinal irradiation

Dosimetric predictors of asymptomatic heart valvular dysfunction follow mediastinal irradiation for Hodgkin's lymphoma

Laura Cella<sup>a,b</sup>, Raffaele Liuzzi<sup>a,b</sup>, Manuel Conson<sup>b</sup>, Gabriella Torre<sup>b</sup>, Michele Caterino<sup>b</sup>, Nicolò Marco Picardi<sup>c</sup>, Luigi Camera<sup>b</sup>, Raffaele Solla<sup>a,b</sup>, Antonio Farella<sup>b</sup>, Marco Salvatore<sup>b</sup>, Roberto

<sup>a</sup>Institute of Biostructure and Bioimaging, National Research Council of Italy (CNR), Naples, Italy; <sup>b</sup>Department of Diagnostic Imaging and Radiation Oncology of Biochemistry and Medical Biotechnology, Federico II University School of Medicine, Naples, Italy

Clinical Investigation: Lymphoma

## Multivariate Normal Tissue Complication Probability Modeling of Heart Valve Dysfunction in Hodgkin Lymphoma Survivors

Laura Cella, PhD,<sup>\*,†</sup> Raffaele Liuzzi, PhD,<sup>\*,†</sup> Manuel Conson, MD,<sup>\*,†</sup> Vittoria D'Avino, MSC,<sup>\*</sup> Marco Salvatore, MD,<sup>†</sup> and Roberto Pacelli, MD<sup>\*</sup>

<sup>\*</sup>Institute of Biostructures and Bioimaging, National Council of Research; and <sup>†</sup>Department of Advanced Sciences, Federico II University School of Medicine, Naples, Italy

OPEN ACCESS Freely available online



## Complication Probability Models for Radiation-Induced Heart Valvular Dysfunction: Do Heart-Lung Interactions Play a Role?

Laura Cella<sup>1,2\*</sup>, Giuseppe Palma<sup>1</sup>, Joseph O. Deasy<sup>3</sup>, Jung Hun Oh<sup>3</sup>, Raffaele Liuzzi<sup>1,2</sup>, Vittoria D'Avino<sup>1</sup>, Manuel Conson<sup>1,2</sup>, Novella Pugliese<sup>4</sup>, Marco Picardi<sup>4</sup>, Marco Salvatore<sup>2</sup>, Roberto Pacelli<sup>1,2</sup>

<sup>1</sup>Institute of Biostructure and Bioimaging, National Council of Research (CNR), Naples, Italy, <sup>2</sup>Department of Advanced Biomedical Sciences, Federico II University School of Medicine, Naples, Italy, <sup>3</sup>Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America, <sup>4</sup>Department of Clinical Medicine and Surgery, Federico II University School of Medicine, Naples, Italy

biology • physics

[www.redjournal.org](http://www.redjournal.org)

*Acta Oncologica*, 2015; Early Online: 1–8

informa  
healthcare

ORIGINAL ARTICLE



Predicting radiation-induced valvular heart damage

LAURA CELLA<sup>1,2</sup>, JUNG HUN OH<sup>3</sup>, JOSEPH O. DEASY<sup>3</sup>, GIUSEPPE PALMA<sup>1</sup>, RAFFAELE LIUZZI<sup>1,2</sup>, VITTORIA D'AVINO<sup>1</sup>, MANUEL CONSON<sup>1,2</sup>, MARCO PICARDI<sup>4</sup>, MARCO SALVATORE<sup>2</sup> & ROBERTO PACELLI<sup>1,2</sup>


<sup>1</sup>Institute of Biostructure and Bioimaging, National Council of Research (CNR), Naples, Italy, <sup>2</sup>Department of Advanced Biomedical Sciences, Federico II University School of Medicine, Naples, Italy, <sup>3</sup>Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA and <sup>4</sup>Department of Clinical Medicine and Surgery, Federico II University School of Medicine, Naples, Italy

## Heart → RESULTS:

- 30% of patients manifested at least one kind of RVD (mild or moderate) at a median time of 55 months (range, 12-92)
- Higher incidence of left-sided RVD(64%)
- The risk of radiation-induce RVD cannot be modeled using NTCP models only based on heart dose-volume distribution (LKB)
- An improved performance can be obtained with the inclusion of clinical variables such as heart and lung volume sizes







$AUC(\log) = 0.8$   
 $AUC(LKB \text{ or } RS) = 0.7$



# $NTCP(\log) =$ $f(\text{HeartDmax}(\text{Gy}), \text{Heart vol}(\text{cc}), \text{lung vol}(\text{cc}))$

NTCP valvular defects for a fixed lung volume (2738 cc)    NTCP valvular defects for a fixed heart volume (521 cc)





Model	Parameter	Estimated coefficient	SE	<i>P</i> value	OR
<b>Model 1</b>					
	Dmax (Gy)	0.1430	0.0751	.043	1.150
	Heart volume (cc)	0.0095	0.0036	.020	1.010
	Lung volume (cc)	-0.0017	0.0006	.011	0.998
	constant	-5.65			



## Improved method for variable selection

- Least absolute shrinkage and Selection operator (LASSO)

$$\max_{(\beta_0, \beta) \in \mathbb{R}^{p+1}} \left[ \sum_{i=1}^n r_i \log p(x_i) + (1 - r_i) \log (1 - p(x_i)) - \lambda \sum_{k=1}^m |\beta_k| \right]$$

Tibshirani (1996), "Regression Shrinkage and Selection via the Lasso"


- Reduce the number of predictors in a generalized linear model.
- Identify important predictors.
- Select among redundant predictors
- Produce shrinkage estimates with potentially lower predictive errors



No	Variable	No	Variable	No	Variable
1	D5 left lung	11	D95 lungs	21	AV30 heart
2	<b>D15 left lung</b>	12	V30 lungs	22	<b>Dmax heart</b>
3	<b>D25 left lung</b>	13	V35 lungs	23	<b>Heart volume</b>
4	<b>D95 left lung</b>	14	AV35 lungs	24	<b>Left lung volume</b>
5	<b>Dmax left lung</b>	15	<b>Dmax lungs</b>	25	Right lung volume
6	<b>D25 right lung</b>	16	<b>D10 heart</b>	26	Lungs volume
7	V30 right lung	17	D35 heart		
8	<b>Dmax right lung</b>	18	<b>V30 heart</b>		
9	D5 lungs	19	AV20 heart		
10	D20 lungs	20	AV25 heart		

Abbreviations: AVX = absolute volume receiving x Gy, Dmax = maximum dose to x% highest dose volume, Vx = percentage volume receiving x Gy, Fr variables are in bold.

Important variables:  
Left lung dose parameters



## Endpoint: RILI $\leftrightarrow$ symptomatic and radiological signs

- RT induces late-phase subclinical injury  $\rightarrow$  fibrosis detectable by CT
- Fibrosis, even if asymptomatic, may progress over several years and decrease lung compliance

Marks, IJROBP 2010

ORIGINAL ARTICLE

**Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury**

LAURA CELLA<sup>1,2</sup>, RAFF  
ANGELA DI BIASE<sup>2</sup>, M/  
MARCO SALVATORE<sup>2</sup> &

Radiotherapy and Oncology xxx (2015) xxx–xxx



ELSEVIER

Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: [www.thegreenjournal.com](http://www.thegreenjournal.com)



Original article

**Modeling the risk of radiation-induced lung fibrosis: Irradiated heart tissue is as important as irradiated lung**



Laura Cella<sup>a,\*</sup>, Vittoria D'Avino<sup>a</sup>, Giuseppe Palma<sup>a</sup>, Manuel Conson<sup>a,b</sup>, Raffaele Liuzzi<sup>a</sup>, Marco Picardi<sup>c</sup>, Maria Cristina Pressello<sup>d</sup>, Genoveva Ionela Boboc<sup>e</sup>, Roberta Battistini<sup>f</sup>, Vittorio Donato<sup>e</sup>, Roberto Pacelli<sup>a,b</sup>

<sup>a</sup>Institute of Biostructure and Bioimaging, National Research Council (CNR); <sup>b</sup>Department of Advanced Biomedical Sciences, Federico II University School of Medicine; <sup>c</sup>Department of Clinical Medicine and Surgery, Federico II University School of Medicine, Naples; <sup>d</sup>Department of Health Physics, S. Camillo-Forlanini Hospital, Rome; <sup>e</sup>Department of Radiation Oncology, S. Camillo-Forlanini Hospital, Rome; and <sup>f</sup>Department of Hematology, S. Camillo-Forlanini Hospital, Rome, Italy


## Lung → RESULTS

- 16% of patients developed radiological changes on CT (any grade of RILI) at a median time of 13 months (range, 9-83)
- 9 patients were symptomatic (50%)
- An area of high probability for RILI incidence can be seen in both lungs and heart DVHs
- Aging along with heart and lungs irradiation plays a fundamental role in the risk of RILI

## Probability maps








Most frequently selected models: competitive models!!!

$AUC1 \approx AUC2 = 0.8$





### Model 1

Parameter	Estimated coefficient	SE	p-Value	OR
Age	.062	.022	.006	1.064
Heart M30 (%)	.026	.009	.004	1.027
Left lung V5 (%)	.027	.016	.094	1.027
Constant	-5.51			

### Performance

Rs	.347
AUC (95% CI)	.78 (.65-.91)
Discrimination value	.20
Calibration slope	.97 ± .11
Calibration intercept	.004 ± .022

### Model 2

Parameter	Estimated coefficient	SE	p-Value	OR
Age	.068	.023	.003	1.070
Heart M30 (%)	.022	.010	.026	1.022
Lung $D_{2\%}$ (Gy)	.115	.084	.171	1.122
Constant	-8.148			

### Performance

Rs	.376
AUC (95% CI)	.80 (.69-.91)
Discrimination value	.18
Calibration slope	1.02 ± .11
Calibration intercept	-.004 ± .022

## CONCLUSIONS

- 1) The importance of lung irradiation and lung volume size in predicting heart toxicity risk.
- 2) The influence of the left lung irradiation on radiation-induced lung fibrosis
- 3) The role of heart irradiation on radiation-induced lung fibrosis
- 4) non-homogeneous lung radiosensitivity

These results obtained in a clinical setting are consistent with those obtained from the Groningen group in animal studies.

The patho-physiological mechanisms of heart-lung interaction in the evolution of late toxicity after thoracic irradiation are still uncertain.



- The obtained models are phenomenological and as such they are consistent with the available data, but the underlying biological mechanisms and causal relations are essentially unknown.
- In several cases, phenomenological models may be an important source of hypothesis-generating information guiding new research

Van der Schaaf et al, Int J Radiat Oncol Biol Phys 2015

## Radiation Oncology research group



Raffaele  
Liuzzi, PhD



Roberto Pacelli, MD &  
Manuel Conson, MD



Vittoria  
D'Avino, MSc



Giuseppe  
Palma, PhD

